8-K: Glucotrack Joins European FORGETDIABETES Initiative to Develop Bionic Pancreas

Glucotrack, Inc. will participate in the FORGETDIABETES initiative, a European research program focused on developing a bionic pancreas for automated insulin delivery.

Summary

• Glucotrack, Inc. (GCTK) announced its participation in the FORGETDIABETES initiative, a European Union-funded project aimed at developing a bionic pancreas.
• The FORGETDIABETES initiative seeks to create an automated insulin delivery system to improve glucose control for individuals with type 1 diabetes.
• Glucotrack's Continuous Blood Glucose Monitor (CBGM) will provide real-time glucose readings to drive insulin delivery decisions for the bionic pancreas system.
• The FORGETDIABETES initiative is funded by the European Union's Horizon 2020 research and innovation program, which has a total budget of 75 Billion.
• The goal is to create a fully implantable closed-loop system that simplifies diabetes management and reduces the burden on patients.

Sentiment

Score: 7

Explanation: The announcement is positive due to Glucotrack's participation in a significant research initiative, but it's tempered by the investigational status of the CBGM and the inherent risks associated with forward-looking statements.

Positives

• Participation in the FORGETDIABETES initiative provides Glucotrack with access to significant funding and research collaboration.
• The bionic pancreas project aligns with Glucotrack's mission to transform diabetes management through innovative technology.
• Integration into automated insulin delivery systems is a key priority for Glucotrack.
• Glucotrack's CBGM offers long-term monitoring with minimal calibration, potentially improving patient convenience.
• The CBGM has a sensor longevity of 3 years, no on-body wearable component and with minimal calibration.

Risks

• The Glucotrack Continuous Blood Glucose Monitor is an Investigational Device and is limited by federal (or United States) law to investigational use.
• The press release contains forward-looking statements that are subject to various risks and uncertainties.
• Glucotrack's ability to raise additional capital, obtain regulatory approvals, and successfully conduct clinical trials could impact its results.
• The company's future distribution agreements and ability to hire and retain qualified personnel are also risk factors.

Future Outlook

Glucotrack is committed to redefining life with diabetes by providing simplified, discreet monitoring through its CBGM and integrating it into automated insulin delivery systems.

Management Comments

• Claudio Cobelli, PhD, Coordinator for the initiative, stated that the longevity, accuracy, and convenience of Glucotrack's CBGM make it an ideal complement for their bionic pancreas technology.
• Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack, said that the company is thrilled to be part of the FORGETDIABETES initiative and committed to transforming diabetes management.

Industry Context

This announcement positions Glucotrack within the growing market for advanced diabetes management solutions, specifically automated insulin delivery systems. The collaboration with a European research initiative could provide a competitive advantage and access to new markets.

Comparison to Industry Standards

• The FORGETDIABETES initiative is similar to other research efforts focused on developing closed-loop insulin delivery systems, such as those by Medtronic, Tandem Diabetes Care, and Insulet.
• Glucotrack's CBGM, with its long-term implantable sensor and minimal calibration, aims to differentiate itself from existing continuous glucose monitoring systems like Dexcom and Abbott.
• The 3-year sensor longevity is a key differentiator compared to existing CGM systems that require more frequent sensor replacements.

Stakeholder Impact

• Shareholders may react positively to the news of Glucotrack's involvement in the FORGETDIABETES initiative.
• People with diabetes could benefit from the development of a bionic pancreas system that simplifies diabetes management.
• Employees of Glucotrack may be motivated by the opportunity to contribute to a groundbreaking research project.

Next Steps

• Glucotrack will continue to collaborate with the FORGETDIABETES partners to develop and integrate its CBGM into the bionic pancreas system.
• The company will likely pursue further clinical trials and regulatory approvals for its CBGM.

Key Dates

Keywords

Glucotrack, FORGETDIABETES, bionic pancreas, continuous blood glucose monitor, diabetes, insulin delivery, Horizon 2020, CBGM